




Improving People's Lives by Treating and Preventing the Clinical Consequences of Vitamin D Insufficiency and Secondary Hyperparathyroidism

Company Overview


Cytochroma Inc. is a clinical stage specialty pharmaceutical company that designs, develops, and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4, or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Research and Development Pipeline

Product	Indication	Research	Preclinical	Phase I	Phase II	Phase III	Partners
Lead Programs							
CTA018	SHPT						 Mitsubishi Tanabe Pharma*
CTAP101	Vit D Insufficiency						none
CTAP201	SHPT						none
Other Programs							
Phosphate Management Products	Hyperphosphatemia						none

*MTPC will co-develop and co-commercialize CTA018 with Cytochroma in the U.S., and has an exclusive royalty-bearing license in Asia.

Investment Highlights



1. IMS, USRDS, Market Research on file, Biotrends Q2/07 Nephrology Update Report

Addressing an Unmet Medical Need

Dialysis patients need effective treatment to:

- Control SHPT and vitamin D insufficiency
- Prevent cardiovascular disease
- Prevent bone and mineral disease

Current therapies do not achieve these goals:

- CKD patients are at increased mortality risk
- Pre-dialysis patients are often not treated for vitamin D insufficiency due to lack of safe or effective treatment choices
- Current therapies may actually cause vitamin D insufficiency
- SHPT remains poorly controlled by current therapies, since less than 11%² of Stage 5 CKD patients meet the targets specified by the National Kidney Foundation in the Kidney Disease Outcomes Quality Initiative (KDOQI™) guidelines

Cytochroma's vitamin D-based therapeutics may provide safe and effective options for pre-dialysis and dialysis patients.

2. Arenas, M et al. Nephrol Dial Transplant (2006) 21: 1663-1668

Chronic Kidney Disease

Chronic kidney disease (CKD) is the progressive loss of kidney function resulting in a decreased ability to filter waste products and maintain a balanced level of fluids and minerals in the blood. This condition is most frequently caused by diabetes or hypertension, both of which are consequences of a growing obesity epidemic worldwide.

Vitamin D Insufficiency

An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to secondary hyperparathyroidism and resultant debilitating diseases including cardiovascular disease, anemia, and hyperphosphatemia. Mounting evidence continues to link vitamin D insufficiency with CKD progression and increased morbidity and mortality in CKD patients.

Secondary Hyperparathyroidism

Secondary hyperparathyroidism (SHPT) is a condition commonly associated with CKD patients in which the parathyroid glands secrete excessive amounts of parathyroid hormone (PTH). Excessive levels of PTH cause calcium to be released from bone and into the blood, leading to softening of the bones (osteomalacia), and calcification of vascular tissues.

Market Opportunity

There are over 20 million patients in the US with Stage 1 to Stage 5 CKD. Cytochroma is currently targeting Stage 3 to Stage 5 CKD patients with SHPT and vitamin D insufficiency.


The SHPT and vitamin D insufficiency market is large and growing rapidly:

Stage	Description	CKD Prevalence	% of CKD Patients with Vit D Insufficiency	% of CKD Patients with SHPT
3	Moderate decrease in kidney function	7,611,000*	70%	40%
4	Severe decrease in kidney function	400,000*	80%	60%
5	Kidney Failure	472,000**	90%	90%

*NKF 2002, **USRDS 2007 ADR

Sources: Levin, A et al., *Kidney International*. Vol. 71 (2007), pp.31-38.
Gonzalez, E et al. *Am J Nephrol* 2004;24:503-510. LaClair, R et al. *Am J Kidney Dis* 45:1026-1033.

The market for vitamin D therapeutics in Stage 5 CKD is currently \$850M and expected to exceed \$1.4 billion annually by 2013 in the US alone, with growing potential in the earlier Stage 3 and 4 CKD patient populations.



Management Team

Charles W. Bishop, PhD

President and Chief Executive Officer

Steven I. Engel, PharmD

Vice President, Regulatory Affairs and Quality Assurance

Bruce McCarty, MBA

Executive Director, Manufacturing Operations

Joel Z. Melnick, MD

Vice President, Clinical Research and Development

Eric J. Messner, MBA

Vice President, Commercial Operations

Gordon Ngan, CFA, MBA

Executive Director, Corporate Development

P. Martin Petkovich, PhD

Chief Scientific Officer

Jay White, PhD

Vice President, Product Development



330 Cochrane Drive
Markham, Ontario, Canada L3R 8E4
Phone: (905) 479-5306 • Fax: (905) 479-1287

2333 Waukegan Road, Suite E100
Bannockburn, Illinois 60015 U.S.A.
Phone: (847) 236-7707 • Fax: (847) 236-9104

General Inquiries:
info@cytochroma.com

Media:
communications@cytochroma.com